MERIT MEDICAL SYSTEMS INC

Merit Medical Systems, Inc. shareholders elected Scott R. Ward to the Board of Directors for a three-year term at the Annual Meeting on May 13, 2026. Shareholders also approved the 2026 Equity Incentive Plan (EIP) and the 2026 Employee Stock Purchase Plan (ESPP), authorizing 2,700,000 and 500,000 shares respectively. The Board adopted Fifth Amended and Restated Bylaws, updating provisions for remote meeting participation, electronic notices, universal proxy rules, and director/officer indemnification. Additionally, shareholders approved executive compensation and ratified Deloitte & Touche LLP as the independent auditor.

Merit Medical Systems, Inc. announced that shareholders elected Scott R. Ward to its Board of Directors for a three-year term at the annual meeting. Ward brings over 40 years of experience in the healthcare and medical device industry, including senior leadership roles at Medtronic and as CEO of Cardiovascular Systems, Inc. He will serve on the company's Governance and Sustainability and Finance and Operating Committees.

Merit Medical Systems, Inc. announced that its management will participate in the Bank of America 2026 Health Care Conference, taking place in Las Vegas, Nevada, from May 12-14, 2026. The management team is scheduled to host a fireside chat session on Tuesday, May 12th, at 3:00 pm Pacific Time. A live audio webcast of the session will be available on the company's investor relations website, with a replay accessible for approximately 90 days.

MERIT MEDICAL SYSTEMS INC reported strong first-quarter 2026 financial results with net income increasing significantly by 35.98% to $40.995 million and net sales growing 7.46% to $381.877 million. The company also completed the divestment of its DualCap® product line for $28 million, realizing a pre-tax book gain of $12.5 million. Additionally, the company has transitioned to a single operating segment and adjusted its product categories to Foundational and Therapeutic.

Merit Medical Systems, Inc. reported strong first-quarter 2026 financial results, with revenue increasing 7% to $381.9 million and GAAP EPS rising 39% to $0.68. The company also announced the divestment of its DualCap® product line for $28 million and the acquisition of View Point Medical for $140 million. Following these developments, MMSI updated its full-year 2026 revenue guidance to $1.612 - $1.634 billion, while maintaining its non-GAAP EPS guidance.

Merit Medical Systems, Inc. provided historical revenue information disaggregated into new foundational and therapeutic product categories. This data covers the years ended December 31, 2022 through 2025, and quarterly periods from Q1 2024 to Q4 2025. The company stated the purpose is to aid period-over-period comparisons for investors and does not constitute a restatement of previously reported financial statements.